Stock Ratings | Rosenblatt initiated coverage of CoreWeave (CRWV) with a "buy" rating, setting a price target of $250 with a potential upside of 153.14%.
Ocular Therapeutix Inc OCUL | 0.00 | |
Amylyx Pharmaceuticals, Inc. AMLX | 0.00 | |
UWM Holdings Corp. Class A UWMC | 0.00 | |
CoreWeave CRWV | 0.00 | |
Gossamer Bio GOSS | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Chardan Capital maintains its "buy" rating on Ocular Therapeutix ( Ocular Therapeutix Inc(OCUL.US) ), raising its price target from $21 to $23.
Guggenheim: Maintaining a "buy" rating on Amylyx Pharmaceuticals ( Amylyx Pharmaceuticals, Inc.(AMLX.US) ), while raising the price target from $30 to $40.
Keefe, Bruyette & Woods: Upgrades UWM Holdings ( UWM Holdings Corp. Class A(UWMC.US) ) to "Outperforms Market", while lowering its price target from $4.50 to $3.75.
Rosenblatt: CoreWeave ( CoreWeave(CRWV.US) ) has a preliminary rating of "buy", with a target price of $250.
HC Wainwright & Co.: Maintaining a "Buy" rating on Gossamer Bio Gossamer Bio(GOSS.US) ) stock, while lowering the price target from $5 to $2.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Ocular Therapeutix Inc(OCUL.US) | to lift | $23.0 | $9.76 | 135.66% | Chardan Capital |
| Amylyx Pharmaceuticals, Inc.(AMLX.US) | to lift | $40.0 | $17.44 | 129.36% | Guggenheim |
| UWM Holdings Corp. Class A(UWMC.US) | to lift | $3.75 | $2.12 | 76.89% | Keefe, Bruyette & Woods |
| Grupo Financiero Galicia SA Sponsored ADR Class B(GGAL.US) | to lift | $85.0 | $49.42 | 72.0% | JP Morgan |
| Ionis Pharmaceuticals, Inc.(IONS.US) | to lift | $130.0 | $78.34 | 65.94% | HC Wainwright & Co. |
| CoreWeave(CRWV.US) | Initial classification | $250.0 | $98.76 | 153.14% | Rosenblatt |
| Gossamer Bio(GOSS.US) | cut | $2.0 | $0.1652 | 1110.65% | HC Wainwright & Co. |
| ARS Pharmaceuticals, Inc.(SPRY.US) | cut | $24.0 | $8.02 | 199.25% | Leerink Partners |
| Celsius Holdings, Inc.(CELH.US) | cut | $57.0 | $28.22 | 101.98% | Roth Capital |
| Lexeo Therapeutics, Inc.(LXEO.US) | cut | $9.0 | $4.7 | 91.49% | JP Morgan |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Evercore ISI Group: Maintaining a "Market Match" rating for American Airlines Group American Airlines Group Inc.(AAL.US) ) stock, while raising its price target from $14 to $17.
HC Wainwright & Co.: Maintaining a "buy" rating on Absci Corporation ( Absci Corporation(ABSI.US) ), with a price target raised from $8 to $16.
Wells Fargo: Maintaining an "overweight" rating on Adient ( Adient plc(ADNT.US) ), while raising the price target from $28 to $32.
Susquehanna: Maintaining a "positive" rating on Affirm Holdings Affirm(AFRM.US) ), while raising the price target from $100 to $105.
First Coverage
RBC Capital: Initial rating for Enact Holdings ( Enact Holdings Inc(ACT.US) ) at "sector match", with a target price of $46.
Lake Street: Initial rating for 万国半导体 ( Alpha and Omega Semiconductor Limited(AOSL.US) ) at "Buy", with a target price of $58.
Keefe, Bruyette & Woods: Initial rating for Arrow Financial ( Arrow Financial Corporation(AROW.US) ) at "Market Match", with a target price of $42.
reduction
Wells Fargo: Maintaining an "overweight" rating on Alcoa ( Alcoa Corporation(AA.US) ), while lowering its price target from $82 to $71.
Morgan Stanley: Downgraded Affirm Affirm(AFRM.US) ) stock to "market-weighted", while maintaining its price target at $79.
Wells Fargo: Maintaining an "overweight" rating on Aptiv ( Aptiv PLC(APTV.US) ) stock, while lowering its price target from $82 to $77.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk warning:
Investing involves risk, and securities prices can rise or fall, or even become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, and risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.